Virion Therapeutics presented preclinical data at the European Association for the Study of Liver Diseases (EASL) annual Congress, showing a direct correlation between vaccine-induced T cells in the liver and hepatitis B virus declines in the blood. The therapeutic vaccine being developed by Virion, VRON-0200, contains key HBV antigens coupled to glycoprotein D (gD), which is a checkpoint modifier of early T cell activation. This is the first time this has been observed for an immune-modulator or a vaccine. A Phase 1b study in chronically HBV-infected patients is scheduled to begin enrollment in Summer 2023.
Virion Therapeutics is a clinical-stage company developing T cell-based immunotherapies for cancer and chronic infectious diseases. The company presented data at EASL 2023 that revealed there's a direct correlation between vaccine-induced T cells in the liver and hepatitis B virus declines in the blood - something that's never been observed before with an immune-modulator or vaccine. The therapeutic vaccine under development by Virion, called VRON-0200, contains key HBV antigens coupled to glycoprotein D (g